Recognizing Hepatitis R & D on World Hepatitis Day
Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. There are five main hepatitis viruses, with types A, B, C most common. In 2018, the Centers for Disease Control and Prevention estimated that Americans were infected with 24,900 cases of hepatitis A and 21,600 cases of hepatitis B, many of which go undiagnosed because individuals do not know they are infected. Over the past several years, the biopharmaceutical industry has made significant progress in bringing medicines to patients that improve cure rates, reduce side effects and duration of treatment and expand treatment options. (Source: The Catalyst)
Source: The Catalyst - July 28, 2021 Category: Pharmaceuticals Tags: Research and Development Drug Cost Hepatitis C Source Type: news

340B hospitals among those that provide lowest levels of community benefit across the country
The 340B program reached$38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014. Unfortunately, despite pharmaceutical manufacturers paying more and more money in 340B discounts, there is no evidence that this growth in 340B translates into lower costs for patients taking prescription medicines. (Source: The Catalyst)
Source: The Catalyst - July 27, 2021 Category: Pharmaceuticals Tags: 340B Hospitals Source Type: news

We Work for Health: Discovering champions, even amid challenging times
For over a decade, We Work For Health has sought to highlight the incredible men and women who create hope for patients, serve as changemakers and ensure the continued vibrancy of our economy. We are proud to celebrate the2021 We Work For Health Employee Champions for the tremendous work they ’ve accomplished. (Source: The Catalyst)
Source: The Catalyst - July 26, 2021 Category: Pharmaceuticals Authors: Ryan Garofalo Tags: Research and Development Source Type: news

Government “negotiation” could have devastating consequences for Medicare enrollees
Some members of Congress are considering significant changes to Medicare that could have adevastating effect on millions of Americans. Proponents call these changes government “negotiation,” but what they are actually proposing is anything but that. These politicians want to repeal a key provision of the Medicare Part D program that protects robust coverage and access to medicines for seniors and people with disabilities. (Source: The Catalyst)
Source: The Catalyst - July 23, 2021 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Part D Medicare Proactive Agenda Source Type: news

Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - July 23, 2021 Category: Pharmaceuticals Authors: Guest Contributor Tags: Vaccines Coronavirus Source Type: news

PhRMA member companies ’ R & D investments reach record high of $91.1 billion in 2020
PhRMA member companies ’ robust investment in research and development (R&D) has led to advances and discoveries that are transforming health care and our approach to treating patients for a broad range of chronic and rare conditions, as well as urgent new health challenges like COVID-19. (Source: The Catalyst)
Source: The Catalyst - July 22, 2021 Category: Pharmaceuticals Authors: Tim McClung Tags: Research and Development Economic Impact PhRMA Member Company Source Type: news

Protecting Medicare from government interference
For more than a decade,Medicare Part D has provided seniors and people with disabilities with affordable and comprehensive prescription medicine coverage. Several surveys show that more than 9 in 10 Part D enrollees are satisfied with their coverage, helping tens of millions of patients manage a number of chronic and life-threatening conditions, including diabetes, mental illness, cancer and heart disease. (Source: The Catalyst)
Source: The Catalyst - July 21, 2021 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Part D Medicare Proactive Agenda Source Type: news

Guest Post: A patient ’s story of the long-term health impacts of COVID-19
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - July 21, 2021 Category: Pharmaceuticals Authors: Guest Contributor Tags: Vaccines Voters for Cures Coronavirus Source Type: news

Ask About Adherence: 3 factors impacting medication adherence for patients with diabetes and how our proactive affordability solutions can help
Earlier this year, PhRMA released aproactive agenda with common-sense, patient-centered reforms to improve access to quality, affordable health care. The urgency of building a stronger, more resilient health care system is apparent in light ofnew data from the U.S. Centers for Disease Control and Prevention that show an increasing number of deaths from heart disease, diabetes and other chronic conditions in the wake of the COVID-19 pandemic. Alarmingly, in 2020, Americans experienced the largest drop in average life expectancysince World War II. (Source: The Catalyst)
Source: The Catalyst - July 20, 2021 Category: Pharmaceuticals Authors: Emilie Signora Tags: Diabetes Out-of-Pocket Costs Proactive Agenda Source Type: news

Dose sharing as a part of the COVID-19 global vaccine equity strategy
The following is part of aseries of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem. (Source: The Catalyst)
Source: The Catalyst - July 20, 2021 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Intellectual Property Vaccines Coronavirus Source Type: news

Data shows voters strongly support protecting access to their medicines
In our current health care system, the Medicare Part D program helps ensure seniors and people with disabilities have access to the prescription medicines they need. While more than 90% of seniors arevery satisfied with their Part D prescription drug coverage and want to protect it, we also must tackle rising out-of-pocket costs for patients at a time when net prices for brand medicinesare declining. (Source: The Catalyst)
Source: The Catalyst - July 15, 2021 Category: Pharmaceuticals Authors: Mark Keida Tags: Part D Medicare Polling Proactive Agenda Source Type: news

Promoting global vaccine equity while protecting innovation
America ’s biopharmaceutical companies have successfully researched, developed and distributed billions of doses of multiple vaccines and therapeutics to halt the spread of COVID-19. The availability of COVID-19 vaccines has shifted the trajectory of the pandemic and is undoubtedly saving lives. Further, the approval of the first ever mRNA vaccines has the potential to usher in an era of groundbreaking mRNA applications beyond COVID-19. (Source: The Catalyst)
Source: The Catalyst - July 15, 2021 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Intellectual Property Vaccines Coronavirus Equity Source Type: news

Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
As we head into the Fourth of July weekend, Americans are reemerging from the COVID-19 pandemic with heightened hopes and confidence in a strong U.S. recovery. The COVID-19 vaccines have been credited with the steep decline in cases nationwide as we reach the lowest rates since the earliest stages of the pandemic. Reliance on safe, effective vaccines can continue to move the needle as we work to control the virus and protect against evolving variants. In 15 states and the District of Columbia,at least 70% of adults have received at least one dose of a COVID-19 vaccine, which is promising news. (Source: The Catalyst)
Source: The Catalyst - July 2, 2021 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Economic Impact Vaccines Coronavirus Polling Source Type: news

PhRMA awards $75,000 to fund initiatives to reduce health inequities
As part of PhRMA ’s continuing commitment to build a more just and equitable health care system, we recently awarded $75,000 through ourCollaborative Actions to Reach Equity (CAREs) grant program to fund three initiatives aimed at reducing inequities and improving health outcomes. (Source: The Catalyst)
Source: The Catalyst - July 1, 2021 Category: Pharmaceuticals Authors: Lori Reilly Tags: Coronavirus Health Equity Source Type: news

Medicare “negotiation” proposals threaten Americans’ access to medicines
Whilemore than 90% of seniors and people with disabilities report that they are very satisfied with their Medicare Part D prescription drug coverage, they also acknowledge concerns with rising out-of-pocket costs. It is no surprise that this has been a recurring discussion on Capitol Hill with many putting forth proposals aimed at lowering the cost of medicines, including principles released by Senator Wyden just last week. Unfortunately, many of these so-called Medicare “negotiation” proposals would create more problems at a time when we can least afford them. (Source: The Catalyst)
Source: The Catalyst - June 30, 2021 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Part D Medicare Proactive Agenda Source Type: news

3 things that support robust biopharmaceutical research and development
Rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, many of the most challenging diseases, including cancer, rare diseases and autoimmune conditions.  (Source: The Catalyst)
Source: The Catalyst - June 29, 2021 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development PDUFA & D Focus Source Type: news

Watch: Building trust and enhancing clinical trial diversity
On June 22, duringThe Atlantic ’s Health Equity Summit, PhRMA hosted aconversation on clinical trial diversity. PhRMA Chief Operating Officer Lori Reilly and Genentech Vice President and Chief Diversity Officer Quita Highsmith discussed how to build greater trust among underserved communities, including communities of color, and how the industry is working to increase clinical trial diversity.  (Source: The Catalyst)
Source: The Catalyst - June 24, 2021 Category: Pharmaceuticals Tags: Research and Development PhRMA Member Company Clinical Trials Health Equity Source Type: news

IP Explained: How does the U.S. patent process work?
Have you ever used a Teflon-coated pan or hit a golf ball down the fairway? Had a friend or family member receive treatment with a new medication? All these products were developed because patents encouraged the R&D that led to these innovations. Patents are a form of intellectual property protection that give inventors the exclusive right to make, use, sell, offer for sale or import their inventions for a set period of time. This alleviates some of the risk inventors take on when developing new products. Patients are well-served by having more inventions protected by intellectual property – it means more co...
Source: The Catalyst - June 24, 2021 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Research and Development Patents IP Explained Source Type: news

Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
Our industry continues to work tirelessly to combat the COVID-19 virus by developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. As we continue our efforts to bring the pandemic to an end, we should not miss the opportunity to learn from it and use those lessons to build a stronger, more resilient, affordable and equitable health care system. (Source: The Catalyst)
Source: The Catalyst - June 23, 2021 Category: Pharmaceuticals Tags: Research and Development PhRMA Member Company Proactive Agenda Source Type: news

More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
We are in a new era of medicine where groundbreaking biopharmaceutical research and development is transforming medicine, but these innovations are meaningless if they don ’t reach patients, including those in underserved communities. Health disparities are not new, but the COVID-19 pandemic put a spotlight on long-standing health inequities that affect diverse racial and ethnic communities in America. Data shows these populations have been disproportionately impact ed by COVID-19. In fact, American Indian/Alaskan Native, Hispanic, and Black populations are approximately twice as likely to die from COVID-19, as compa...
Source: The Catalyst - June 22, 2021 Category: Pharmaceuticals Tags: Medicines in Development Research and Development Coronavirus Health Equity Source Type: news

New PhRMA Scholars program provides support to exceptional college-bound DC students
As part of our continued efforts to promote diversity, equity and inclusion, we ’re excited to announce thePhRMA Scholars program and the exceptional students who received this year ’s awards.  (Source: The Catalyst)
Source: The Catalyst - June 18, 2021 Category: Pharmaceuticals Authors: Rachel Weissman Tags: Equity Source Type: news

Americans 12 years of age and older are eligible for COVID-19 vaccines
Last month, the U.S. Food and Drug Administration (FDA) granted an expansion of an emergency use authorization on one of the COVID-19 vaccines allowing Americans 12-15 years of age and older to be eligible to receive the one of the COVID-19 vaccines. Following this positive news, the Advisory Committee on Immunization Practices also recommended this expansion.  (Source: The Catalyst)
Source: The Catalyst - June 17, 2021 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Vaccines Coronavirus Source Type: news

Researchers to shine light on biopharmaceutical R & D with policymakers
Today, biopharmaceutical researchers from PhRMA member companies are meeting virtually with members of Congress and staff to share their stories of transforming game-changing scientific discoveries into new treatments and cures for patients. They represent hundreds of thousands of biopharmaceutical researchers working throughout the United States who are at the heart of America ’s robust research and developmentecosystem, developing more innovative medicines than any other country in the world. Their work is often late into the night in labs where they relentlessly pursue new avenues of resea...
Source: The Catalyst - June 15, 2021 Category: Pharmaceuticals Tags: Research and Development PhRMA Member Company Source Type: news

PhRMA hosts first stakeholder workshop on clinical trial diversity
This week, 500+ health care and community members from over 150 organizations came together at PhRMA ’s first stakeholder workshop focused on improving diversity in clinical trials. At the virtual workshop, titled “Partnering for Health Equity: Advancing Research Through Representative Clinical Trials, ” participants joined breakout discussions, panels and facilitated conversations designed to pressure test actionable ideas to enhance clinical trial diversity. Topics included: (Source: The Catalyst)
Source: The Catalyst - June 14, 2021 Category: Pharmaceuticals Tags: Clinical Trials Coronavirus Health Equity Source Type: news

PhRMA hosts first public workshop on clinical trial diversity
This week, 500+ health care and community members from over 150 organizations came together at PhRMA ’s first stakeholder workshop focused on improving diversity in clinical trials. At the virtual workshop, titled “Partnering for Health Equity: Advancing Research Through Representative Clinical Trials, ” participants joined breakout discussions, panels and facilitated conversations designed to pressure test actionable ideas to enhance clinical trial diversity. Topics included: (Source: The Catalyst)
Source: The Catalyst - June 11, 2021 Category: Pharmaceuticals Tags: Clinical Trials Coronavirus Health Equity Source Type: news

How research evolves and brings new hope to patients
Before medicines can be made available to patients, they often begin as ideas that are based on newly discovered molecules and cells, strange phenomena or little-understood processes in the body. The biopharmaceutical industry ’s unique role in theresearch ecosystem is to utilize its scientific, medical and industrial expertise to take the necessary risks to build on and translate basic scientific research into safe and effective medicines that can be made available to patients. This long and complex process is regularly fraught with more setbacks than successes asless than 12% of medicines entering phase one clinica...
Source: The Catalyst - June 11, 2021 Category: Pharmaceuticals Tags: Research and Development Alzheimer's Source Type: news

Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage  Therapeutics
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. A key piece of that has been the impact the pandemic has had on mental health.  (Source: The Catalyst)
Source: The Catalyst - June 9, 2021 Category: Pharmaceuticals Tags: Mental Health Coronavirus Source Type: news

New reports shed light on  key facts about medicines and affordability
A recently released report by IQVIA  – an independent organization specializing in health care research – provides new data showing prices for brand medicines went down last year. The report offers important facts to keep in mind as policymakers look to make health care more affordable. According to the report: (Source: The Catalyst)
Source: The Catalyst - June 8, 2021 Category: Pharmaceuticals Authors: Brian Newell Tags: Drug Cost Out-of-Pocket Costs Source Type: news

Continued R & D into Alzheimer ’s disease means hope for patients, families and caregivers
More than 6 million Americans, most of them age 65 or older, live with Alzheimer ’s disease, a devastating degenerative brain disease and the most common form of dementia. After heart disease and cancer, Alzheimer’s disease is thethird leading cause of death for seniors, responsible for one out of every three deaths. Not only do patients need an effective treatment and cure, but the health care system does, too. Alzheimer ’s burden isexpected to cost the nation more than $1.1 trillion by 2050. (Source: The Catalyst)
Source: The Catalyst - June 4, 2021 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development Alzheimer's Source Type: news

A year later: Reflections on the meaning of equity
A year later — (Source: The Catalyst)
Source: The Catalyst - May 25, 2021 Category: Pharmaceuticals Authors: Courtney Christian Tags: Coronavirus Equity Source Type: news

Out-of-pocket trends in Medicare Part D show rising costs for seniors
Anew study based on IQVIA data shows alarming trends in rising out-of-pocket costs for brand medicines among Medicare Part D beneficiaries with serious and complex conditions like cancer, HIV and multiple sclerosis. The analysis, which looked at spending trends among non-low-income subsidy (non-LIS) Part D beneficiaries from 2015 to 2019 across all brand medicines and several therapeutic areas, reaffirms the need for targeted solutions to strengthen the program. Here are three findings you should know.  (Source: The Catalyst)
Source: The Catalyst - May 24, 2021 Category: Pharmaceuticals Authors: Katie Koziara Tags: Part D Out-of-Pocket Costs Source Type: news

ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
On May 19, Axios hosted anevent discussing the unprecedented development of COVID-19 vaccines and the road ahead. Speakers included NIAID Director Dr. Anthony Fauci, Pfizer Chairman& CEO Dr. Albert Bourla and PhRMA President& CEO Stephen J. Ubl. View the event here: (Source: The Catalyst)
Source: The Catalyst - May 21, 2021 Category: Pharmaceuticals Tags: Vaccines Coronavirus Source Type: news

Supporting India during the devastating coronavirus surge
Like many others around the world, America ’s biopharmaceutical companies stand with those affected by the coronavirus. And while biopharmaceutical companies areworking around the clock to meet the demands of COVID-19 by developing and delivering therapeutics and vaccines, we recognize that the coronavirus crisis in India requires urgent attention and collaborative solutions from stakeholders globally.  (Source: The Catalyst)
Source: The Catalyst - May 20, 2021 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Vaccines Coronavirus Source Type: news

Creating a new patient risk paradigm in American health care
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - May 18, 2021 Category: Pharmaceuticals Authors: Guest Contributor Tags: Research and Development Value Assessment Equity Source Type: news

How strengthening the biosimilar marketplace benefits patients
Biologics are medicines that are made from living organisms through highly complex manufacturing processes and include a wide variety of medicines such as therapeutic proteins, monoclonal antibodies and vaccines. They are used to prevent or treat a variety of diseases including cancer, chronic kidney disease, diabetes, cystic fibrosis and autoimmune disorders.  (Source: The Catalyst)
Source: The Catalyst - May 18, 2021 Category: Pharmaceuticals Tags: FDA Drug Cost Biologics and Biosimilars Source Type: news

Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs
According to arecent survey by Verpora that will be presented this week atISPOR, nearly half of U.S. payers surveyed expressed a belief that wider implementation ofinnovative contracts could lead to lower patient out-of-pocket costs across small molecule, biologic, cell and gene therapies. This echoes the support biopharmaceutical companies have for these innovative contracts, and recent studies that demonstrate the potential impact value-based approaches can have on improving patient health outcomes, decreasing payer costs andlowering patient out-of-pocket spending.  (Source: The Catalyst)
Source: The Catalyst - May 17, 2021 Category: Pharmaceuticals Authors: Katie Koziara Tags: Out-of-Pocket Costs The Value Collaborative Value-Based Contracting Source Type: news

New polling shows Americans are sounding the alarm on the TRIPS IP waiver
Last week, the Biden administration announced support for a waiver of the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which could lead to the removal of intellectual property protections for manufacturers of COVID-19 vaccines and treatments – a move some have suggested will speed global access in countries devastated by recent surges.  (Source: The Catalyst)
Source: The Catalyst - May 14, 2021 Category: Pharmaceuticals Authors: Cynthia Hicks Tags: Patents Intellectual Property Trade COVID-19 Source Type: news

The Biden Administration allows politics to upend a pragmatic pandemic response
Last week, the Biden Administration announced that it will support a waiver of the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which would waive intellectual property (IP) protections for COVID-19 vaccines. Not only will this policydo nothing to help save lives globally, it could have a damaging impact for American patients.  (Source: The Catalyst)
Source: The Catalyst - May 14, 2021 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Patents Intellectual Property Trade COVID-19 Source Type: news

The ABCs (and Ds) of Medicare
For nearly 60 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans with certain medical needs. Medicare has many different programs, all named with different letters of the alphabet, so it can often feel confusing. With Medicare increasingly in the news, clarity around how it works and what types of health care it covers is important. We ’re here to break it down and share the basics about the different parts of Medicare:  (Source: The Catalyst)
Source: The Catalyst - May 13, 2021 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Part D Medicare Part B Source Type: news

Four solutions Americans support to make health care more affordable
Health care costs and affordability remain a major challenge for most Americans, even among those with insurance. According to aMarch Gallup poll, nearly one-in-five (18%) U.S. adults report that if they needed access to quality health care today, they would be unable to pay for it. The arrival of the COVID-19 crisis has only underscored the challenges facing patients, demonstrating that Americans are in need of a more affordable solution.  (Source: The Catalyst)
Source: The Catalyst - May 13, 2021 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Policy Solutions Polling Proactive Agenda Source Type: news

The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - May 12, 2021 Category: Pharmaceuticals Authors: Guest Contributor Tags: FDA Equity Proactive Agenda Source Type: news

New report demonstrates development of new medicines relies on private sector expertise and investment
America ’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. Critical to this ecosystem is the working relationship between industry and government agencies like the National Institutes of Health (NIH), academic medical centers and community-based research sites to further the translation of basic research into important medical products.  (Source: The Catalyst)
Source: The Catalyst - May 10, 2021 Category: Pharmaceuticals Authors: John Corea Tags: Research and Development Intellectual Property Drug Cost Source Type: news

PhRMA CAREs Grant request for proposals:  Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. (Source: The Catalyst)
Source: The Catalyst - May 6, 2021 Category: Pharmaceuticals Authors: Guest Contributor Tags: Vaccines COVID-19 Health Equity Source Type: news

A conversation with Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in communities of color
The COVID-19 pandemic exposed and often exacerbated the significant systemic health inequities that underserved communities have faced for many years. Black Americans have been particularly affected by these inequalities. These inequities and resulting disparities foster mistrust and contribute to vaccine hesitancy. (Source: The Catalyst)
Source: The Catalyst - May 5, 2021 Category: Pharmaceuticals Tags: Vaccines Coronavirus Equity Source Type: news

American leadership on innovation policy is essential to global health progress
Over the last year, the world has witnessed the importance of strong innovation policies as intellectual property protection and market access policies facilitated the research, development and distribution ofCOVID-19 diagnostics, treatments and vaccines. Innovative medicines are now making their way to patients around the world, demonstrating remarkableprogress andcollaboration at a scale that was unimaginable at the start of the pandemic, including more than 200 manufacturing and other partnerships to date. (Source: The Catalyst)
Source: The Catalyst - May 4, 2021 Category: Pharmaceuticals Authors: Ernest Kawka Tags: Intellectual Property Trade COVID-19 Source Type: news

Reflecting on Mental Health Awareness Month
As communities around the world continue to grapple with the impact of COVID-19, the importance of furthering our understanding of the impact on our mental health is undeniable. (Source: The Catalyst)
Source: The Catalyst - May 4, 2021 Category: Pharmaceuticals Tags: Research and Development Mental Illness Coronavirus Source Type: news

H.R. 3 threatens access to medicines, future innovation and American jobs
In the last election, voters made clear that they want quality, affordable health coverage that works when they need it and lower out-of-pocket costs for medicines. And we can achieve those goals, but the drug pricing plan known as H.R. 3 is not the answer. If implemented, it could have devastating consequences for patients ’ access to medicines, future innovation and American jobs. Put simply, H.R. 3 is the wrong approach for both patients and the U.S. health care system. Here are some reasons why: (Source: The Catalyst)
Source: The Catalyst - May 4, 2021 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Policy Solutions International Reference Pricing Proactive Agenda Source Type: news

New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging
The discovery and introduction of antibiotics in the 1940s transformed modern medicine and enabled tremendous progress in health care and life expectancy. Today, this progress is being threatened by a health crisis on the rise: antimicrobial resistance (AMR). AMR affects at least 3 million Americans and results in 48,000 U.S. deaths annually. The World Bank Group ’s 2017 report on drug-resistant infections estimates that unless action is taken, AMR globally could take 10 million lives annually by 2050, a higher toll than from cancer. If we fail to address the crisis, many modern medical advances that depend on antibi...
Source: The Catalyst - April 29, 2021 Category: Pharmaceuticals Tags: Medicines in Development Research and Development & D Focus Antimicrobial Resistance Source Type: news

New data from insurers show detriments of copay accumulator adjustment programs
Commercial health insurers are starting to admit what the biopharmaceutical research industry has been warning for some time: copay accumulator adjustment programs hurt patient outcomes and shift costs onto patients at the pharmacy counter. Those are some of the key findings from two new surveys that help demonstrate why these programs don ’t serve the best interests of patients. (Source: The Catalyst)
Source: The Catalyst - April 28, 2021 Category: Pharmaceuticals Authors: Katie Koziara Tags: Out-of-Pocket Costs Let's Talk About Cost Source Type: news

Patient safety is at the heart of COVID-19 vaccine R & D
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is continuingworking around the clock to research, develop and manufacture vaccines to prevent infection. To date, substantial progress has been made in vaccinating Americans with COVID-19 vaccines that have been granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA). (Source: The Catalyst)
Source: The Catalyst - April 26, 2021 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development Vaccines Coronavirus Source Type: news